Articles related to MELANOMA

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

A total of 168 patients were randomly assigned to receive tumor-infiltrating lymphocytes (TILs) (84 patients) or ipilimumab (84 patients). The median progression-free survival in the TIL group was 7.2 months and 3.1 months in the ipilimumab group; 49% and 21% of the patients, respectively, had an objective response. The TIL group had a median overall survival of 25.8 months, while the ipilimumab group had a median overall survival of 18.9 months.

According to a study presented at the 2022 ASCO Quality Care Symposium, 27% of 159 patients in the sample who received inpatient immune checkpoint inhibitor (ICI) treatment passed away while still in the hospital, with the median overall survival for the entire group being 47 days. Thoracic or head and neck cancers (27%) were the most prevalent, with gastrointestinal cancers (20%), hematologic malignancies (18%), genitourinary cancers (17%), and melanoma (11%) rounding out the rest.

The researchers put a theory to the test by administering the compound CBL0137 to melanoma mouse models. This compound causes the same type of highly inflammatory cell death that the influenza virus causes, but it does so directly in cancerous tissue. The resulting antiviral response alerted the immune system. It heated up a “cold” tumor so that, when combined with immunotherapy, the host immune system recognized cancer as something to be destroyed.

In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.

168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.